LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Digital Pathology Solution Provides Truly Interoperable Platform to Streamline Workflow

By LabMedica International staff writers
Posted on 11 Oct 2022
Print article
Image: PathFlow Viewer and Automated Workflow are now European regulatory cleared for use in primary diagnosis (Photo courtesy of Gestalt)
Image: PathFlow Viewer and Automated Workflow are now European regulatory cleared for use in primary diagnosis (Photo courtesy of Gestalt)

Gestalt Diagnostics, Inc. (Spokane, WA, USA) has received CE-IVD marks for two of the main components of PathFlow. Both the PathFlow viewer and the proprietary, automated workflows now have European regulatory clearance for broad use in clinical, education, and research laboratories. Gestalt's PathFlow is a universal, easy-to-use digital platform for pathology laboratories that enables pathologists to interpret, and diagnose patient cases quickly, efficiently, and in a fully automated fashion. Gestalt provides the enterprise solutions, and services, to transform anatomic pathology laboratories from glass slides, microscopes, and couriers to a fully interoperable, automated, electronic digital workflow.

The European regulatory certification of the key components of Gestalt's PathFlow provides the support some healthcare facilities need to fully deploy and recognize the value of digital pathology throughout their organizations. Gestalt's feature-rich viewer is consistent throughout all the PathFlow modules whether clinical, education, or research and provides the pathologist or scientist with access to all of the information related to their case, study, or course in a single, streamlined environment.

"A truly interoperable platform which incorporates every component necessary to streamline the workflow for pathologists is essential for leveraging the full benefits of digital pathology," said Lisa-Jean Clifford, COO & Chief Strategy Officer at Gestalt. "The receipt of these CE-IVD marks is an important milestone for our company in providing the assurance that our solutions meet the regulatory standards required for patient care while increasing speed and efficiency for their providers."

Related Links:
Gestalt Diagnostics, Inc. 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more